The University of Kansas Cancer Center requests CCSG funds for developmental funds to be specifically used for the pilot studies program and to supplement new recruitment packages. The major purpose of the Pilot Studies Program is to provide support for highly innovative research proposals in new, exciting, and potentially breakthrough areas of cancer research. The pilot research proposal must be cancer-related and must not overlap with existing funding from any source (different focus and different aims). Ultimately, the goal is to have these funds provide critical preliminary data to test new hypotheses and assess feasibility of ideas that might allow for rapid advancement in the field and make an impact in basic, clinical, or translational research. The merit of these proposals will be assessed by members of the KUCC-Leadership Council and approved by the Director prior to funding. To actively build and improve our research environment, KUCC is committed to recruiting additional cancer researchers to increase the national and international status of the Cancer Center, enhance the number of NCI/cancer-related grants, fill critical research positions and build the four cancer research programs. Each purposeful hire aims to further the scientific vision, mission, and goals of the Cancer Center research programs. The funds requested will be used to supplement the recruitment packages of future cancer center recruits and will be leveraged by matching with Kansas Bioscience Authority funds.
The University of Kansas Cancer Center plans to utilize developmental funds to continue and to supplement its highly successful pilot project program to provide funding to test new research ideas. In addition, we will use a portion of the funds to supplement recruitment packages for new investigators.
| Gonzalez-Mercado, Velda J; Fridley, Brooke L; Saligan, Leorey N (2018) Sestrin family of genes and their role in cancer-related fatigue. Support Care Cancer 26:2071-2074 |
| Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620 |
| Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7: |
| Lea, Wendy A; Parnell, Stephen C; Wallace, Darren P et al. (2018) Human-Specific Abnormal Alternative Splicing of Wild-Type PKD1 Induces Premature Termination of Polycystin-1. J Am Soc Nephrol 29:2482-2492 |
| Hirst, Jeff; Pathak, Harsh B; Hyter, Stephen et al. (2018) Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties. Cancer Res 78:4370-4385 |
| Trinca, Gloria M; Goodman, Merit L; Papachristou, Evangelia K et al. (2018) O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer. Horm Cancer 9:12-21 |
| Subramaniam, Dharmalingam; Kaushik, Gaurav; Dandawate, Prasad et al. (2018) Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer. Curr Med Chem 25:2585-2594 |
| Beadnell, Thomas C; Scheid, Adam D; Vivian, Carolyn J et al. (2018) Roles of the mitochondrial genetics in cancer metastasis: not to be ignored any longer. Cancer Metastasis Rev : |
| Li, Linda Xiaoyan; Zhou, Julie Xia; Calvet, James P et al. (2018) Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. Cell Death Dis 9:326 |
| Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38: |
Showing the most recent 10 out of 177 publications
